---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-026780"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2026-06-02T12:48:18+00:00"
generated_at: "2026-06-02T12:50:11.103008+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions starts multi-site FDA 510(k) study for opiate codeine fingerprint test

## Summary
- Study will enroll 135 donor participants across multiple sites; partnered with CenExel Clinical Research.
- Designed to validate accuracy, sensitivity, specificity of the Intelligent Fingerprinting Drug Screening System for workplace use.
- Company expects to complete enrollment and data collection by end of July 2026.
- User performance evaluation by non-laboratory personnel is a key part of the 510(k) submission.
- Results will be confirmed via LC-MS/MS; study follows ICH GCP guidelines.

## SEC filing metadata
- accession: 0001493152-26-026780
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2026-06-02T12:48:18+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315226026780/0001493152-26-026780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315226026780/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-026780
- JSON: https://secwatch.observer/filing/0001493152-26-026780.json
- Plain text: https://secwatch.observer/filing/0001493152-26-026780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.